Skip to main content
Fig. 3 | BMC Women's Health

Fig. 3

From: Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients

Fig. 3

Patient Global Impression of Change (PGIC) at month 3 for integrated Elaris EM-I and Elaris EM-II by baseline demographic subgroups. PGIC uses a 7-point scale ranging from 1 = very much improved through 7 = very much worse. p values were obtained from a logistic regression model: “very much” or “much improved/otherwise” = treatment + subgroup + treatment × subgroup. p values for between-group comparisons were obtained using a contrast within the subgroup from the logistic regression model. *p < 0.05. Green indicates placebo, purple indicates elagolix 150 mg QD, and orange indicates elagolix 200 mg BID. BID twice daily; BMI body mass index; QD once daily

Back to article page